Trovagene Inc(TROV)stock report

Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers. PCM-075 developed high selectivity to PLK1, to be administered orally, and to have a relatively short drug half-life of approximately 24 hours compared to other PLK inhibitors. PCM-075 has completed a safety study in patients with advanced metastatic solid tumors with a phase Ib/II clinical trial in patients with AML underway.

Current cash: 9.03M, Latest quarter loss: 4.15M,可以烧1年。

EPS and Sales:

Date EPS % last year % last quarter
2018.12.31 -8.26 84.04% 0.12%
 2019.3.31 -1.02 83.63% 87.65%
2019.6.30 -1.78 84.21% -74.51%
 2019.9.30 -2.46 70.25% -38.20%


Date Sales % last year % last quarter
2018.12.31 0.38 -25.14% 21.05%
 2019.3.31 0.16 61.74% -57.89%
2019.6.30 0.3 41.66% 87.50%
 2019.9.30 0.15 -49.37% -50.00%


Insider Transactions:

Institution Ownership:


Analyst Ratings:

Leave a Reply